新冠病毒感染诊疗方案第十版发布，诊治方案之争尘埃落地了吗？_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

 刘春涛

四川大学华西医院·华西天府医院（四川成都 610041）;

Corresponding author：

刘春涛, Email: taosen666@vip.163.com

Keywords：

DOI：

10.7507/1671-6205.202301027

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 刘春涛. 新冠病毒感染诊疗方案第十版发布，诊治方案之争尘埃落地了吗？. Chinese Journal of Respiratory and Critical Care Medicine, 2023, 22(1): 1-6. doi: 10.7507/1671-6205.202301027 Copy

1.	Lu G, Ling Y, Jiang MH, et al. Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in China mainland[J/OL]. Front Med. (2022-12-29) https://journal.hep.com.cn/fmd/EN/10.1007/s11684-022-0981-7.
2.	国家卫生健康委员会国家中医药管理局. 新型冠状病毒肺炎诊疗方案 (试行第九版)[EB/OL]. http://www.gov.cn/zhengce/zhengceku/2022-03/15/5679257/files/49854a49c7004f4ea9e622f3f2c568d8.pdf.
3.	中华医学会呼吸病分会危重症学组中国医师协会呼吸医师分会危重症医学专家组. 奥密克戎变异株所致重型新型冠状病毒感染临床救治专家推荐意见[J/OL]. 中华结核和呼吸杂志. (2023-01-04) https://rs.yiigle.com/yufabiao/1442297.htm.
4.	国家卫生健康委员会国家中医药管理局. 新型冠状病毒感染诊疗方案 (试行第十版) [EB/OL]. (2023-01-06) http://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a/files/02ec13aadff048ffae227593a6363ee8.pdf.
5.	国家卫生健康委员会国家中医药管理局. 新型冠状病毒感染重症病例诊疗方案(试行第四版)[EB/OL]. (2023-01-13) http://www.nhc.gov.cn/xcs/zhengcwj/202301/ad34a9b598654b90a5c8c99440cce21b/files/754297ec20cd40eebb7fe18828d8ed31.pdf.
6.	The ITAC (INSIGHT 013) Study Group. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet, 2022, 399(10324): 530-540.
7.	Rahmel T, Kraft F, Haberl H, et al. Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study. Crit Care, 2022, 26(1): 204.
8.	Mazeraud A, Jamme M, Mancusi RL, et al. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med, 2022, 10(2): 158-166.
9.	The REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med, 2021, 384(16): 1491-1502.
10.	Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med, 2021, 9(12): 1407-1418.

1. Lu G, Ling Y, Jiang MH, et al. Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in China mainland[J/OL]. Front Med. (2022-12-29) https://journal.hep.com.cn/fmd/EN/10.1007/s11684-022-0981-7.
2. 国家卫生健康委员会国家中医药管理局. 新型冠状病毒肺炎诊疗方案 (试行第九版)[EB/OL]. http://www.gov.cn/zhengce/zhengceku/2022-03/15/5679257/files/49854a49c7004f4ea9e622f3f2c568d8.pdf.
3. 中华医学会呼吸病分会危重症学组中国医师协会呼吸医师分会危重症医学专家组. 奥密克戎变异株所致重型新型冠状病毒感染临床救治专家推荐意见[J/OL]. 中华结核和呼吸杂志. (2023-01-04) https://rs.yiigle.com/yufabiao/1442297.htm.
4. 国家卫生健康委员会国家中医药管理局. 新型冠状病毒感染诊疗方案 (试行第十版) [EB/OL]. (2023-01-06) http://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a/files/02ec13aadff048ffae227593a6363ee8.pdf.
5. 国家卫生健康委员会国家中医药管理局. 新型冠状病毒感染重症病例诊疗方案(试行第四版)[EB/OL]. (2023-01-13) http://www.nhc.gov.cn/xcs/zhengcwj/202301/ad34a9b598654b90a5c8c99440cce21b/files/754297ec20cd40eebb7fe18828d8ed31.pdf.
6. The ITAC (INSIGHT 013) Study Group. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet, 2022, 399(10324): 530-540.
7. Rahmel T, Kraft F, Haberl H, et al. Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study. Crit Care, 2022, 26(1): 204.
8. Mazeraud A, Jamme M, Mancusi RL, et al. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med, 2022, 10(2): 158-166.
9. The REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med, 2021, 384(16): 1491-1502.
10. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med, 2021, 9(12): 1407-1418.

Next Article
Therapeutic effect of hemoperfusion for absorption of inflammatory cytokines on sepsis

Chinese Journal of Respiratory and Critical Care Medicine

新冠病毒感染诊疗方案第十版发布，诊治方案之争尘埃落地了吗？

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content